TW202525320A - 用於處置或預防中樞神經系損傷疾病的環狀胜肽衍生物組成物 - Google Patents

用於處置或預防中樞神經系損傷疾病的環狀胜肽衍生物組成物 Download PDF

Info

Publication number
TW202525320A
TW202525320A TW112142064A TW112142064A TW202525320A TW 202525320 A TW202525320 A TW 202525320A TW 112142064 A TW112142064 A TW 112142064A TW 112142064 A TW112142064 A TW 112142064A TW 202525320 A TW202525320 A TW 202525320A
Authority
TW
Taiwan
Prior art keywords
group
hydrogen atom
composition
mmol
mixture
Prior art date
Application number
TW112142064A
Other languages
English (en)
Chinese (zh)
Inventor
松本恒平
大西海斗
寺上佳奈
苅田祐馬
田部七大
安井航佑
正司武嗣
Original Assignee
日商第一工業製藥股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 日商第一工業製藥股份有限公司 filed Critical 日商第一工業製藥股份有限公司
Publication of TW202525320A publication Critical patent/TW202525320A/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/12—Cyclic peptides with only normal peptide bonds in the ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
TW112142064A 2022-11-04 2023-11-01 用於處置或預防中樞神經系損傷疾病的環狀胜肽衍生物組成物 TW202525320A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2022-177714 2022-11-04
JP2022177714 2022-11-04

Publications (1)

Publication Number Publication Date
TW202525320A true TW202525320A (zh) 2025-07-01

Family

ID=90930657

Family Applications (1)

Application Number Title Priority Date Filing Date
TW112142064A TW202525320A (zh) 2022-11-04 2023-11-01 用於處置或預防中樞神經系損傷疾病的環狀胜肽衍生物組成物

Country Status (7)

Country Link
EP (1) EP4613282A1 (https=)
JP (1) JPWO2024096066A1 (https=)
KR (1) KR20250111317A (https=)
CN (1) CN120152726A (https=)
IL (1) IL320606A (https=)
TW (1) TW202525320A (https=)
WO (1) WO2024096066A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202547546A (zh) * 2024-02-07 2025-12-16 日商第一工業製藥股份有限公司 用以改善腦功能之環狀肽衍生物組成物

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4172896A (en) 1978-06-05 1979-10-30 Dainippon Pharmaceutical Co., Ltd. Methane-sulfonamide derivatives, the preparation thereof and composition comprising the same
GB9217295D0 (en) 1992-08-14 1992-09-30 Wellcome Found Controlled released tablets
US5541231A (en) 1993-07-30 1996-07-30 Glaxo Wellcome Inc. Stabilized Pharmaceutical
GB9315856D0 (en) 1993-07-30 1993-09-15 Wellcome Found Stabilized pharmaceutical
US5358970A (en) 1993-08-12 1994-10-25 Burroughs Wellcome Co. Pharmaceutical composition containing bupropion hydrochloride and a stabilizer
DE69839355T2 (de) 1997-07-29 2009-06-04 Alcon Laboratories, Inc., Fort Worth Ophthalmische Zusammensetzungen enthaltend Galaktomannanpolymere und Borat
AU2483599A (en) 1998-01-29 1999-08-16 Sepracor, Inc. Pharmaceutical uses of optically pure (-)-bupropion
US8889112B2 (en) 1999-09-16 2014-11-18 Ocularis Pharma, Llc Ophthalmic formulations including selective alpha 1 antagonists
US6933289B2 (en) 2003-07-01 2005-08-23 Allergan, Inc. Inhibition of irritating side effects associated with use of a topical ophthalmic medication
EP1654002B2 (en) 2003-08-07 2014-01-29 Allergan, Inc. Compositions for delivery of therapeutics into the eyes
US20050059744A1 (en) 2003-09-12 2005-03-17 Allergan, Inc. Methods and compositions for the treatment of pain and other alpha 2 adrenergic-mediated conditions
WO2016047638A1 (ja) * 2014-09-24 2016-03-31 国立大学法人岩手大学 環状ペプチド誘導体とその製造方法および組成物
JP7486328B2 (ja) * 2020-03-05 2024-05-17 株式会社バイオコクーン研究所 神経突起伸長促進剤、神経細胞の樹状突起発現促進剤、及び神経栄養因子様作用物質
JP7695662B2 (ja) * 2020-11-02 2025-06-19 公立大学法人大阪 環状ペプチド誘導体の製造方法及び環状ペプチド化合物の製造方法

Also Published As

Publication number Publication date
JPWO2024096066A1 (https=) 2024-05-10
WO2024096066A1 (ja) 2024-05-10
KR20250111317A (ko) 2025-07-22
EP4613282A1 (en) 2025-09-10
IL320606A (en) 2025-07-01
CN120152726A (zh) 2025-06-13

Similar Documents

Publication Publication Date Title
CN102459185B (zh) 新型甲状腺激素β受体激动剂
JP6419990B2 (ja) ブロモドメイン阻害剤としてのベンゾイミダゾール誘導体
JP4024309B2 (ja) 新規な感染症治療薬
JPWO1998017625A1 (ja) 新規な感染症治療薬
TWI471322B (zh) 新穎醯胺衍生物及其作為醫藥之用途
CN111135171A (zh) 与毒性醛相关的疾病和治疗
WO2020063824A1 (zh) 硝羟喹啉前药及其用途
JP7564528B2 (ja) 狂犬病の治療のための化合物およびその方法
JPH11501288A (ja) 金属タンパク質分解酵素阻害剤
CN115867545A (zh) 抗病毒素1,3-二氧代茚化合物
TW201020249A (en) Synthetic mimetics of host defense and uses thereof
TW202525320A (zh) 用於處置或預防中樞神經系損傷疾病的環狀胜肽衍生物組成物
US12310955B2 (en) Cyclic amide compounds for rabies treatment and method thereof
WO2025067477A1 (zh) 抗鲍曼不动杆菌的环肽及其应用
HK40128045A (zh) 用於处置或预防中枢神经系统损伤疾病的环状肽衍生物组合物
TW202423948A (zh) 環狀胜肽衍生物與其製造方法以及組成物
TW202506167A (zh) 用以處置或預防神經障礙性疼痛及／或炎症性疼痛的環狀胜肽衍生物組成物
TW202430203A (zh) 用於處置或預防眼科疾病的環狀胜肽衍生物組成物
TW202547546A (zh) 用以改善腦功能之環狀肽衍生物組成物
HK40129190A (zh) 用於处置或预防神经病理性疼痛和/或炎性疼痛的环状肽衍生物组合物
HK40122917A (zh) 环状肽衍生物及其制造方法和组合物
TW202545557A (zh) 用以調節睪固酮之產生／分泌的環狀肽衍生物組成物
WO2025252247A1 (zh) Gspt1降解剂抗体偶联物
WO2024235205A1 (zh) 噻唑类衍生物抑制剂、其制备方法和应用
HK40088484A (zh) 抗病毒素1，3-二氧代茚化合物